Marie-Ange Mouret-Reynier

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Tyrosine Kinase

Top Venues

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, Justine Cinier, Yasmine Lounici, Isabelle Treilleux, Pierre-Alexandre Just, Guillaume Bataillon, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Elodie Coquan, Olfa Derbel, Louis Jeay, Suliman Bouizaguen, Sana Intidhar Labidi-Galy, Séverine Tabone-Eglinger, Anthony Ferrari, Emilie Thomas, Christine Ménétrier-Caux, Eric Tartour, Isabelle Galy-Fauroux, Marc-Henri Stern, Magali Terme, Christophe Caux, Bertrand Dubois, Isabelle L Ray-Coquard
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, Justine Cinier, Yasmine Lounici, Isabelle Treilleux, Pierre-Alexandre Just, Guillaume Bataillon, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Elodie Coquan, Olfa Derbel, Louis Jeay, Suliman Bouizaguen, Sana Intidhar Labidi-Galy, Séverine Tabone-Eglinger, Anthony Ferrari, Emilie Thomas, Christine Ménétrier-Caux, Eric Tartour, Isabelle Galy-Fauroux, Marc-Henri Stern, Magali Terme, Christophe Caux, Bertrand Dubois, Isabelle L Ray-Coquard
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, Justine Cinier, Yasmine Lounici, Isabelle Treilleux, Pierre-Alexandre Just, Guillaume Bataillon, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Elodie Coquan, Olfa Derbel, Louis Jeay, Suliman Bouizaguen, Sana Intidhar Labidi-Galy, Séverine Tabone-Eglinger, Anthony Ferrari, Emilie Thomas, Christine Ménétrier-Caux, Eric Tartour, Isabelle Galy-Fauroux, Marc-Henri Stern, Magali Terme, Christophe Caux, Bertrand Dubois, Isabelle L Ray-Coquard
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature communications 15 (1) (2024)
Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, Stéphanie Durand, Angélique Abila, Delphine Centeno, Charlotte Joly, Bernard Lyan, Anne-Laure Martin, Sibille Everhard, Sandrine Boyault, Barbara Pistilli, Marion Fournier, Philippe Rouanet, Julie Havas, Baptiste Sauterey, Mario Campone, Carole Tarpin, Marie-Ange Mouret-Reynier, Olivier Rigal, Thierry Petit, Christine Lasset, Aurélie Bertaut, Paul-Henri Cottu, Fabrice Andre, Ines Vaz Luis, Estelle Pujos-Guillot, Youenn Drouet, Olivier Trédan
Metabolomic prediction of breast cancer treatment induced neurological and metabolic toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, Justine Cinier, Yasmine Lounici, Isabelle Treilleux, Pierre-Alexandre Just, Guillaume Bataillon, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Elodie Coquan, Olfa Derbel, Louis Jeay, Suliman Bouizaguen, Sana Intidhar Labidi-Galy, Séverine Tabone-Eglinger, Anthony Ferrari, Emilie Thomas, Christine Ménétrier-Caux, Eric Tartour, Isabelle Galy-Fauroux, Marc-Henri Stern, Magali Terme, Christophe Caux, Bertrand Dubois, Isabelle L Ray-Coquard
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)